Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study.

Mallayasamy S, Chaturvedula A, Blaschke T, Fossler MJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):818-828. doi: 10.1002/psp4.12361. Epub 2018 Oct 28.

2.

Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies.

Yang S, Beerahee M.

Eur J Clin Pharmacol. 2011 Mar;67(3):225-33. doi: 10.1007/s00228-010-0957-4. Epub 2010 Dec 2.

PMID:
21125264
3.

Bayesian population modeling of drug dosing adherence.

Fellows K, Stoneking CJ, Ramanathan M.

J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):515-25. doi: 10.1007/s10928-015-9439-8. Epub 2015 Aug 29.

PMID:
26319548
4.

Adherence to Internet-Based Mobile-Supported Stress Management: A Pooled Analysis of Individual Participant Data From Three Randomized Controlled Trials.

Zarski AC, Lehr D, Berking M, Riper H, Cuijpers P, Ebert DD.

J Med Internet Res. 2016 Jun 29;18(6):e146. doi: 10.2196/jmir.4493.

5.

Medication Nonadherence, "Professional Subjects," and Apparent Placebo Responders: Overlapping Challenges for Medications Development.

McCann DJ, Petry NM, Bresell A, Isacsson E, Wilson E, Alexander RC.

J Clin Psychopharmacol. 2015 Oct;35(5):566-73. doi: 10.1097/JCP.0000000000000372. Review.

6.

Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.

Hénin E, Tod M, Trillet-Lenoir V, Rioufol C, Tranchand B, Girard P.

Clin Pharmacokinet. 2009;48(6):359-69. doi: 10.2165/00003088-200948060-00002.

PMID:
19650675
7.

Designing complex group sequential survival trials.

Lakatos E.

Stat Med. 2002 Jul 30;21(14):1969-89.

PMID:
12111882
8.

Statement of the problem and pharmacological and clinical requirements for the ideal marker.

Insull W Jr.

Control Clin Trials. 1984 Dec;5(4 Suppl):459-62.

PMID:
6518771
9.

Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches.

Juul RV, Nyberg J, Kreilgaard M, Christrup LL, Simonsson USH, Lund TM.

J Pharmacokinet Pharmacodyn. 2017 Aug;44(4):325-333. doi: 10.1007/s10928-017-9522-4. Epub 2017 Apr 7.

PMID:
28389762
10.

Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.

Ogungbenro K, Aarons L.

J Biopharm Stat. 2010 Sep;20(5):1026-42. doi: 10.1080/10543401003619205.

PMID:
20721789
11.

Mitigating the Effects of Nonadherence in Clinical Trials.

Shiovitz TM, Bain EE, McCann DJ, Skolnick P, Laughren T, Hanina A, Burch D.

J Clin Pharmacol. 2016 Sep;56(9):1151-64. doi: 10.1002/jcph.689. Epub 2016 Jan 22.

12.

Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.

Larsen MS, Juul RV, Kreilgaard M, Kristensen AT, Simonsson USH.

Eur J Pharm Sci. 2018 Oct 15;123:531-538. doi: 10.1016/j.ejps.2018.07.056. Epub 2018 Aug 3.

PMID:
30077714
13.

An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.

Mi MY, Betensky RA.

Clin Trials. 2013 Apr;10(2):207-15. doi: 10.1177/1740774512468806. Epub 2013 Jan 2.

15.

Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review.

Zedler BK, Kakad P, Colilla S, Murrelle L, Shah NR.

Clin Ther. 2011 Jan;33(1):62-73. doi: 10.1016/j.clinthera.2011.02.003. Review.

PMID:
21397775
16.
17.

Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.

Gieschke R, Steimer JL.

Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):49-58.

PMID:
11032091
19.

The impact of compliance in pharmacokinetic studies.

Vrijens B, Goetghebeur E.

Stat Methods Med Res. 1999 Sep;8(3):247-62.

PMID:
10636337
20.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578

Supplemental Content

Support Center